Federico Hinestrosa

2.5k total citations
28 papers, 404 citations indexed

About

Federico Hinestrosa is a scholar working on Infectious Diseases, Epidemiology and Hepatology. According to data from OpenAlex, Federico Hinestrosa has authored 28 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Infectious Diseases, 10 papers in Epidemiology and 10 papers in Hepatology. Recurrent topics in Federico Hinestrosa's work include HIV/AIDS drug development and treatment (17 papers), Hepatitis C virus research (10 papers) and HIV Research and Treatment (7 papers). Federico Hinestrosa is often cited by papers focused on HIV/AIDS drug development and treatment (17 papers), Hepatitis C virus research (10 papers) and HIV Research and Treatment (7 papers). Federico Hinestrosa collaborates with scholars based in United States, France and South Africa. Federico Hinestrosa's co-authors include Charlotte-Paige Rolle, Vu Cong Nguyen, Edwin DeJesus, Mark Sulkowski, K. Peter Etzkorn, Paul J. Thuluvath, Mitchell Davis, Diana M. Brainard, John G. McHutchison and John McNally and has published in prestigious journals such as The Lancet, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Federico Hinestrosa

25 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Federico Hinestrosa United States	10	295	278	160	47	36	28	404
Ana Arizcorreta Spain	7	382 1.3×	316 1.1×	108 0.7×	44 0.9×	49 1.4×	12	428
Josep M. Guardiola Spain	11	324 1.1×	273 1.0×	184 1.1×	79 1.7×	22 0.6×	25	423
María José Galindo Spain	6	220 0.7×	218 0.8×	132 0.8×	21 0.4×	36 1.0×	9	314
Laura Loiacono Italy	9	327 1.1×	318 1.1×	76 0.5×	30 0.6×	20 0.6×	18	447
Roberto Rossotti Italy	9	151 0.5×	174 0.6×	190 1.2×	55 1.2×	13 0.4×	45	377
Maria José Ríos-Villegas Spain	14	570 1.9×	502 1.8×	218 1.4×	78 1.7×	57 1.6×	28	692
Álvaro Mena Spain	12	337 1.1×	334 1.2×	241 1.5×	120 2.6×	40 1.1×	52	551
Russell Fleischer United States	7	678 2.3×	693 2.5×	157 1.0×	23 0.5×	24 0.7×	7	779
C. Cooper Canada	12	246 0.8×	244 0.9×	132 0.8×	47 1.0×	18 0.5×	21	337
Almudena Torres-Cornejo Spain	11	202 0.7×	176 0.6×	157 1.0×	108 2.3×	21 0.6×	28	337

Countries citing papers authored by Federico Hinestrosa

Since Specialization

Citations

This map shows the geographic impact of Federico Hinestrosa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Hinestrosa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Hinestrosa more than expected).

Fields of papers citing papers by Federico Hinestrosa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Hinestrosa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Hinestrosa. The network helps show where Federico Hinestrosa may publish in the future.

Co-authorship network of co-authors of Federico Hinestrosa

This figure shows the co-authorship network connecting the top 25 collaborators of Federico Hinestrosa. A scholar is included among the top collaborators of Federico Hinestrosa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federico Hinestrosa. Federico Hinestrosa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Colson, Amy E., Anthony Mills, Christopher Bettacchi, et al.. (2026). Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. The Lancet. 407(10528). 611–621. 1 indexed citations

Lillis, Rebecca, Christy M. Boraas, Steven Chavoustie, et al.. (2025). Evaluation of Mycoplasma genitalium positivity and co-infection with Chlamydia trachomatis and/or Neisseria gonorrhoeae at various care sites across the United States. International Journal of Infectious Diseases. 162. 108228–108228.

Rockstroh, Jürgen K., Roger Paredes, Pedro Cahn, et al.. (2025). Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial. Clinical Infectious Diseases. 81(2). 322–332.

Molina, Jean‐Michel, Giuliano Rizzardini, Catherine Orrell, et al.. (2024). Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial. The Lancet HIV. 11(6). e369–e379. 10 indexed citations

Pol, Barbara Van Der, Christy M. Boraas, Steven Chavoustie, et al.. (2024). A-359 Clinical Performance Evaluation of the Polymerase Chain Reaction (PCR)-Based cobas CT/NG/MG Test for Use on the cobas liat System in a Clinical Laboratory Setting and Point-of-Care (POC) Location. Clinical Chemistry. 70(Supplement_1).

Rolle, Charlotte-Paige, et al.. (2024). Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study. Open Forum Infectious Diseases. 11(10). ofae560–ofae560. 2 indexed citations

Rolle, Charlotte-Paige, et al.. (2023). 1603. Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Rolle, Charlotte-Paige, et al.. (2021). Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV. Medicine. 100(38). e27330–e27330. 35 indexed citations

Rolle, Charlotte-Paige, Vu Cong Nguyen, Federico Hinestrosa, & Edwin DeJesus. (2021). Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV. AIDS Research and Therapy. 18(1). 26–26. 9 indexed citations

10.

Huhn, Gregory, Moti Ramgopal, Mamta K. Jain, et al.. (2020). HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. PLoS ONE. 15(1). e0224875–e0224875. 5 indexed citations

11.

Rolle, Charlotte-Paige, Vu Cong Nguyen, Federico Hinestrosa, & Edwin DeJesus. (2020). Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting. Journal of Virus Eradication. 6(4). 100021–100021. 4 indexed citations

12.

Lok, Anna S., Mark Sulkowski, Jens Kort, et al.. (2019). Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology. 157(6). 1506–1517.e1. 34 indexed citations

13.

Lok, A.S., Ira Willner, Federico Hinestrosa, et al.. (2018). A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/− ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy. Journal of Hepatology. 68. S104–S104. 1 indexed citations

14.

Hinestrosa, Federico, et al.. (2018). Update of Hepatitis C in Colombia. Current Tropical Medicine Reports. 5(3). 133–137. 1 indexed citations

15.

Gane, Edward, Mitchell L. Shiffman, K. Peter Etzkorn, et al.. (2017). Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen. Hepatology. 66(4). 1083–1089. 60 indexed citations

16.

Gane, Edward, K. Peter Etzkorn, G. Morelli, et al.. (2016). Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study. Journal of Hepatology. 64(2). S147–S148. 23 indexed citations

17.

Everson, Gregory T., William Towner, Mitchell Davis, et al.. (2015). Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection. Annals of Internal Medicine. 4 indexed citations

18.

Sulkowski, Mark, David Gardiner, E. Läwitz, et al.. (2012). 1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3. Journal of Hepatology. 56. S560–S560. 70 indexed citations

19.

Hinestrosa, Federico, Svetolik Djurkovic, Paul Bourbeau, & Michael Foltzer. (2006). Propionibacterium acnes as a Cause of Prosthetic Valve Aortic Root Abscess. Journal of Clinical Microbiology. 45(1). 259–261. 17 indexed citations

20.

Hinestrosa, Federico, et al.. (2006). OBESITY IS ASSOCIATED WITH IMPROVED SURVIVAL IN CRITICALLY ILL PATIENTS WITH BLOOD STREAM INFECTIONS. CHEST Journal. 130(4). 220S–220S. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact